{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:18:00Z","timestamp":1788351480439,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clcc.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:21:53Z","timestamp":1781652113000},"page":"403-413.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Bevacizumab and Chemoradiotherapy for Locally Advanced Rectal Cancer: Long-Term Outcomes of a Multicentre Study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-2386","authenticated-orcid":false,"given":"Ilaria","family":"Prata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris D.","family":"Nagtegaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H.W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Graham","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.J.","family":"Hutschemaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vanhoutvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Cats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie A.M.","family":"Marijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2026.06.002_bib0001","doi-asserted-by":"crossref","DOI":"10.48101\/ujms.v129.10537","article-title":"Recent advances in rectal cancer treatment - are we on the right track?","volume":"129","author":"Glimelius","year":"2024","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.clcc.2026.06.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2024.15","article-title":"Novel radiation and targeted therapy combinations for improving rectal cancer outcomes","volume":"26","author":"Pennel","year":"2024","journal-title":"Expert Rev Mol Med"},{"issue":"7","key":"10.1016\/j.clcc.2026.06.002_bib0003","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(24)00203-1","article-title":"Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study","volume":"25","author":"Yu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2026.06.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.05.254","article-title":"247P Radiotherapy (RT), atezolizumab (atezo) and bevacizumab (bev) to increase organ preservation in rectal cancer: the TARZAN study","volume":"35","author":"De Gooyer","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clcc.2026.06.002_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2026.06.002_bib0006","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem AC","year":"2014","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.clcc.2026.06.002_bib0007","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.clcc.2026.06.002_bib0008","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"Willett","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.06.002_bib0009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-015-1053-z","article-title":"A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features","volume":"15","author":"Salazar","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2026.06.002_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12885-015-1052-0","article-title":"Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer","volume":"15","author":"Garc\u00eda","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clcc.2026.06.002_bib0011","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1634\/theoncologist.2010-0285","article-title":"Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study","volume":"16","author":"Nogu\u00e9","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2026.06.002_bib0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1748-717X-6-105","article-title":"Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study","volume":"6","author":"Velenik","year":"2011","journal-title":"Radiat Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2026.06.002_bib0013","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clcc.2026.06.002_bib0014","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijrobp.2015.02.016","article-title":"Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy","volume":"92","author":"Pollom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clcc.2026.06.002_bib0015","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.21037\/tlcr-20-552","article-title":"Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents","volume":"10","author":"Wrona","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2026.06.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.15040","article-title":"Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: a feasibility study of the Dutch Colorectal Cancer Group (DCCG)","volume":"26","author":"Marijnen","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.06.002_bib0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ssu.10017","article-title":"TNM, sixth edition: new developments in general concepts and rules","volume":"21","author":"Sobin","year":"2003","journal-title":"Semin Surg Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.06.002_bib0018","doi-asserted-by":"crossref","first-page":"dju248","DOI":"10.1093\/jnci\/dju248","article-title":"Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment","volume":"106","author":"Trakarnsanga","year":"2014","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2026.06.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101964","article-title":"How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement","volume":"84","author":"Nagtegaal","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.clcc.2026.06.002_bib0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/his.15027","article-title":"Relevance of shrinkage versus fragmented response patterns in rectal cancer","volume":"83","author":"Kus Ozturk","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.clcc.2026.06.002_bib0021","unstructured":"National Cancer Institute. (CTEP) CTEP, ed. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: U.S. Department of Health and Human Services; 2006."},{"issue":"1","key":"10.1016\/j.clcc.2026.06.002_bib0022","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10456-011-9250-0","article-title":"A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer","volume":"15","author":"Gasparini","year":"2012","journal-title":"Angiogenesis"},{"issue":"5","key":"10.1016\/j.clcc.2026.06.002_bib0023","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.21873\/anticanres.11617","article-title":"Neoadjuvant chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab followed by concomitant chemoradiation and surgical resection in locally advanced rectal cancer with high risk of recurrence - a phase II study","volume":"37","author":"Eisterer","year":"2017","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.clcc.2026.06.002_bib0024","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jjco\/hyy029","article-title":"Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity","volume":"48","author":"Wee","year":"2018","journal-title":"Jap J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clcc.2026.06.002_bib0025","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/cncr.34836","article-title":"Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2026.06.002_bib0026","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2013.10.031","article-title":"A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer","volume":"132","author":"Viswanathan","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"25","key":"10.1016\/j.clcc.2026.06.002_bib0027","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2009.21.8529","article-title":"Phase II study of Bevacizumab with concurrent capecitabine and radiation followed by maintenance Gemcitabine and Bevacizumab for locally advanced pancreatic cancer: radiation Therapy Oncology Group RTOG 0411","volume":"27","author":"Crane","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clcc.2026.06.002_bib0028","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdt124","article-title":"Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer","volume":"24","author":"Van Dijk","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.06.002_bib0029","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2026.06.002_bib0030","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.06.002_bib0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.06.002_bib0032","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.3390\/curroncol29050297","article-title":"Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis","volume":"29","author":"Liao","year":"2022","journal-title":"Curr Oncol"},{"issue":"24","key":"10.1016\/j.clcc.2026.06.002_bib0033","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1200\/JCO.2005.08.144","article-title":"Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate","volume":"23","author":"Folkesson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.06.002_bib0034","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000257358.56863.ce","article-title":"The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma","volume":"246","author":"Peeters","year":"2007","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.clcc.2026.06.002_bib0035","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"issue":"15","key":"10.1016\/j.clcc.2026.06.002_bib0036","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.06.002_bib0037","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clcc.2026.06.002_bib0038","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.06.002_bib0039","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/his.14644","article-title":"Shrinkage versus fragmentation response in neoadjuvantly treated oesophageal adenocarcinoma: significant prognostic relevance","volume":"80","author":"Graham Martinez","year":"2022","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.clcc.2026.06.002_bib0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.clcc.2026.06.002_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076866","volume":"13","author":"Geubels","year":"2023","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.clcc.2026.06.002_bib0042","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ejso.2020.04.014","article-title":"Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians. Do clinicians know what patients want?","volume":"46","author":"van der Valk","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.clcc.2026.06.002_bib0043","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis","volume":"2","author":"Dossa","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clcc.2026.06.002_bib0044","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/DCR.0000000000003484","article-title":"Effectiveness of organ preservation for locally advanced rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: Bayesian Network meta-analysis","volume":"68","author":"Ouyang","year":"2025","journal-title":"Dis Colon Rectum"},{"issue":"17","key":"10.1016\/j.clcc.2026.06.002_bib0045","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without Bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.clcc.2026.06.002_bib0046","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clcc.2026.06.002_bib0047","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.clcc.2026.06.002_bib0048","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clcc.2026.06.002_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.clcc.2026.06.002_bib0050","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clcc.2026.06.002_bib0051","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13046-021-02043-0","article-title":"Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth","volume":"40","author":"Doleschel","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.clcc.2026.06.002_bib0052","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clcc.2026.06.002_bib0053","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clcc.2026.06.002_bib0054","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"2_suppl","key":"10.1016\/j.clcc.2026.06.002_bib0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2026.44.2_suppl.14","volume":"44","author":"Lima","year":"2026","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clcc.2026.06.002_bib0056","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clon.2021.06.006","article-title":"Intensified total neoadjuvant therapy in patients with locally advanced rectal cancer: a phase II trial","volume":"33","author":"De Felice","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clcc.2026.06.002_bib0057","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2019.01.006","article-title":"Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial","volume":"110","author":"Masi","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:40:07Z","timestamp":1788349207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1533002826000472"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.06.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Bevacizumab and Chemoradiotherapy for Locally Advanced Rectal Cancer: Long-Term Outcomes of a Multicentre Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}